Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Erasca, Inc. (ERAS)
USD17.90
-0.63 (-3.40%)
US NASDAQ Healthcare Biotechnology
Address
10835 Road to the Cure 92121
San Diego, CA, US
San Diego, CA, US
CEO
Jonathan E. Lim
Website
erasca.com
IPO
2021-07-16
CIK 1761918 ISIN US29479A1088
Description
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
News Sentiment (7d)
51 articles
- ERAS INVESTOR DEADLINE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - HBSS PRNewsWire
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ERAS Newsfile Corp
- ROSEN, SKILLED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ERAS GlobeNewsWire
- Erasca (ERAS) Faces Securities Class Action After Stock Declines 48% on Drug Safety and IP Concerns-- HBSS GuruFocus
- Bragar Eagel & Squire, P.C. Reminds Erasca, Inc. (ERAS) Investors that a Class Action Lawsuit Has Been Filed Against Erasca and Encourages Investors to Contact the Firm Globe News Wire
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD17.90
-0.63 (-3.40%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
7M
Beta
0.67
Float Shares
186.79M
Free Float %
60.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.57% | -0.86% | -36.36% | -13.50% | +308.66% | +179.03% | +680.45% | +250.68% | -40.45% | -40.45% | -40.45% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (11 ratings, all time)
Buy
Price Targets & DCF
Current price
17.90
Low
10.00
-44.1%
Consensus
17.80
-0.6%
Median
12.00
-33.0%
High
30.00
+67.6%
DCF (Unlevered)
0.10
-99.4%
DCF (Levered)
0.09
-99.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
80% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 6 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
30.00
+67.6%
|
| Last Quarter | 2 |
25.00
+39.7%
|
| Last Year | 12 |
10.00
-44.1%
|
| All Time | 15 |
9.20
-48.6%
|
Quality scores
Altman Z-Score
24.06
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+36.2% ★ Q1'26: -445.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-136.6% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+21.3% Q1'26: +7.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.37× Q1'26: -0.06× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 8 EPS Ana. |
Dec 2027 5 Rev. Ana. 7 EPS Ana. |
Dec 2028 6 Rev. Ana. 6 EPS Ana. |
Dec 2029 5 Rev. Ana. 4 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est: 817.8K (-100.0%)
|
7.52M
7.52M – 7.52M
+818.9% YoY
|
375.0K
375.0K – 375.0K
-95.0% YoY
|
3.67M
3.67M – 3.67M
+877.8% YoY
|
37.39M
37.39M – 37.39M
+919.6% YoY
|
245.06M
245.06M – 245.06M
+555.5% YoY
|
| EBITDA |
-153.28M
|
-128.30M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-157.09M
|
-131.41M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-161.65M
est: -178.54M (+9.5%)
|
-124.55M
est: -124.55M (+0.0%)
|
-172.28M
-331.31M – -167.70M
-38.3% YoY
|
-181.07M
-206.61M – -128.04M
-5.1% YoY
|
-222.03M
-248.39M – -136.48M
-22.6% YoY
|
-220.59M
-220.59M – -220.59M
+0.6% YoY
|
-95.83M
-95.83M – -95.83M
+56.6% YoY
|
| SGA |
41.73M
|
38.55M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-0.69
est: -0.73 (+5.3%)
|
-0.44
est: -0.44 (+0.9%)
|
-0.74
-1.17 – -0.59
-65.7% YoY
|
-0.55
-0.73 – -0.45
+24.7% YoY
|
-0.65
-0.88 – -0.48
-17.5% YoY
|
-0.78
-0.78 – -0.78
-19.4% YoY
|
-0.34
-0.34 – -0.34
+56.6% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-27 | Stifel | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
65
Total invested
350.00M
Insider transactions (90d)
0
Beneficial owners (>5%)
45
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Jonathan E. Lim | 32.06M | 26.40% | — | 32.06M | — | 32.06M | IN | — | 2022-02-14 | ↗ |
| 2 | Conyee T. Lim | 20.16M | 16.60% | — | 20.16M | — | 20.16M | IN | — | 2022-02-14 | ↗ |
| 3 | 85-4328500 | 16.83M | 6.00% | 16.83M | — | 16.83M | — | IA | Maryland | 2024-11-14 | ↗ |
| 4 | Koh, Bong | 16.22M | 6.50% | — | 16.22M | — | — | IN | Delaware | 2024-05-31 | ↗ |
| 5 | Shah, Nimish | 16.22M | 6.50% | — | 16.22M | — | — | IN | Delaware | 2024-05-31 | ↗ |
| 6 | VHCP Co-Investment Holdings III, LLC | 16.22M | 6.50% | — | 16.22M | — | — | OO | Delaware | 2024-05-31 | ↗ |
| 7 | VHCP Management EG, LLC | 16.22M | 6.50% | — | 16.22M | — | — | OO | Delaware | 2024-05-31 | ↗ |
| 8 | VHCP Management III, LLC | 16.22M | 6.50% | — | 16.22M | — | — | OO | Delaware | 2024-05-31 | ↗ |
| 9 | Venrock Healthcare Capital Partners EG, L.P. | 16.22M | 6.50% | — | 16.22M | — | — | PN | Delaware | 2024-05-31 | ↗ |
| 10 | Venrock Healthcare Capital Partners III, L.P. | 16.22M | 6.50% | — | 16.22M | — | — | PN | Delaware | 2024-05-31 | ↗ |
| 11 | James N. Topper | 16.22M | 5.90% | — | 16.22M | — | 16.22M | IN | Delaware | 2024-05-29 | ↗ |
| 12 | Patrick J. Heron | 16.22M | 5.90% | — | 16.22M | — | 16.22M | IN | Delaware | 2024-05-29 | ↗ |
| 13 | (1) BlackRock, Inc. | 15.36M | 5.40% | 14.98M | — | — | 14.98M | HC | Delaware | 2024-11-08 | ↗ |
| 14 | Aaron Cowen | 13.77M | 5.50% | — | 13.77M | — | 13.77M | HC, IN | Delaware | 2024-05-28 | ↗ |
| 15 | Averill Master Fund, Ltd. | 13.77M | 5.50% | — | 13.77M | — | 13.77M | CO | Delaware | 2024-05-28 | ↗ |
| 16 | Suvretta Capital Management, LLC | 13.77M | 5.50% | — | 13.77M | — | 13.77M | IA, OO | Delaware | 2024-05-28 | ↗ |
| 17 | Novartis AG | 12.31M | 8.20% | — | 12.31M | — | — | HC, CO | Switzerland | 2022-12-19 | ↗ |
| 18 | Novartis Pharma AG | 12.31M | 8.20% | — | 12.31M | — | — | CO | Switzerland | 2022-12-19 | ↗ |
| 19 | City Hill, LLC | 11.90M | 9.80% | — | 11.90M | — | 11.90M | OO | — | 2022-02-14 | ↗ |
| 20 | Albert Cha | 11.77M | 4.30% | — | 11.77M | — | 11.77M | IN | Delaware | 2024-05-29 | ↗ |
| 21 | James Brush | 11.77M | 4.30% | — | 11.77M | — | 11.77M | IN | Delaware | 2024-05-29 | ↗ |
| 22 | ARCH Venture Fund X Overage, L.P. | 11.06M | 9.10% | — | 11.06M | — | 11.06M | PN | Delaware | 2022-02-10 | ↗ |
| 23 | ARCH Venture Fund X, L.P. | 11.06M | 9.10% | — | 11.06M | — | 11.06M | PN | Delaware | 2022-02-10 | ↗ |
| 24 | ARCH Venture Partners X Overage, L.P. | 11.06M | 9.10% | — | 11.06M | — | 11.06M | PN | Delaware | 2022-02-10 | ↗ |
| 25 | ARCH Venture Partners X, LLC | 11.06M | 9.10% | — | 11.06M | — | 11.06M | OO | Delaware | 2022-02-10 | ↗ |
| 26 | Crandell | 11.06M | 9.10% | — | 11.06M | — | 11.06M | IN | United States of America | 2022-02-10 | ↗ |
| 27 | Gillis | 11.06M | 9.10% | — | 11.06M | — | 11.06M | IN | United States of America | 2022-02-10 | ↗ |
| 28 | Kristina Burow | 11.06M | 9.10% | — | 11.06M | — | 11.06M | IN | States of America | 2022-02-10 | ↗ |
| 29 | FHMLSP, L.L.C. | 10.59M | 3.90% | — | 10.59M | — | 10.59M | OO | Delaware | 2024-05-29 | ↗ |
| 30 | FHMLSP, L.P. | 10.59M | 3.90% | — | 10.59M | — | 10.59M | PN | Delaware | 2024-05-29 | ↗ |
| 31 | Frazier Life Sciences Public Fund, L.P. | 10.59M | 3.90% | — | 10.59M | — | 10.59M | PN | Delaware | 2024-05-29 | ↗ |
| 32 | Armistice Capital, LLC | 8.10M | 5.36% | — | 8.10M | — | — | IA, OO | Delaware | 2024-02-14 | ↗ |
| 33 | Steven Boyd | 8.10M | 5.36% | — | 8.10M | — | — | HC, IN | Delaware | 2024-02-14 | ↗ |
| 34 | OO CUSIP No. A108 Schedule G Page of Colt Second Erasca Partners, LLC | 6.49M | 5.35% | — | 6.49M | — | 6.49M | OO | Texas | 2022-03-18 | ↗ |
| 35 | Daniel Estes | 3.03M | 1.10% | — | 3.03M | — | 3.03M | IN | Delaware | 2024-05-29 | ↗ |
| 36 | FHMLS XI, L.L.C. | 3.03M | 1.10% | — | 3.03M | — | 3.03M | OO | Delaware | 2024-05-29 | ↗ |
| 37 | FHMLS XI, L.P. | 3.03M | 1.10% | — | 3.03M | — | 3.03M | PN | Delaware | 2024-05-29 | ↗ |
| 38 | Frazier Life Sciences XI, L.P. | 3.03M | 1.10% | — | 3.03M | — | 3.03M | PN | Delaware | 2024-05-29 | ↗ |
| 39 | FHMLS X, L.L.C. | 1.42M | 0.50% | — | 1.42M | — | 1.42M | OO | Delaware | 2024-05-29 | ↗ |
| 40 | FHMLS X, L.P. | 1.42M | 0.50% | — | 1.42M | — | 1.42M | PN | Delaware | 2024-05-29 | ↗ |
| 41 | Frazier Life Sciences X, L.P. | 1.42M | 0.50% | — | 1.42M | — | 1.42M | PN | Delaware | 2024-05-29 | ↗ |
| 42 | FHMLSP Overage, L.L.C. | 1.18M | 0.40% | — | 1.18M | — | 1.18M | OO | Delaware | 2024-05-29 | ↗ |
| 43 | FHMLSP Overage, L.P. | 1.18M | 0.40% | — | 1.18M | — | 1.18M | PN | Delaware | 2024-05-29 | ↗ |
| 44 | Frazier Life Sciences Public Overage Fund, L.P. | 1.18M | 0.40% | — | 1.18M | — | 1.18M | PN | Delaware | 2024-05-29 | ↗ |
| 45 | 2. | 10.00 | 6.30% | — | 7.75M | — | — | IA, PN | Delaware | 2022-09-06 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
65
-93 vs prev Q
New positions
29
Closed positions
117
Increased
50
Reduced
9
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 3.89M +3.9M (+100.0%) | 14.47B +14.5B (+100.0%) | 1.37% +1.371 pp | 4.78% +4.781 pp | USD3.72 +0.0% | 1 qtrs NEW |
| 2 | EP WEALTH ADVISORS, LLC | 30.0K +30.0K (+100.0%) | 111.60M +111.6M (+100.0%) | 0.01% +0.011 pp | 0.00% +0.001 pp | USD3.72 +0.0% | 1 qtrs NEW |
| 3 | FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 22.73M +— (+0.0%) | 84.55M +35.0M (+70.6%) | 8.01% -0.009 pp | 2.27% +0.786 pp | USD2.32 +60.3% | 7 qtrs — |
| 4 | VR ADVISER, LLC | 17.86M +— (+0.0%) | 66.43M +27.5M (+70.6%) | 6.29% -0.007 pp | 3.28% +1.090 pp | USD2.33 +59.7% | 7 qtrs — |
| 5 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 16.11M -4.1M (-20.4%) | 59.94M +15.8M (+35.9%) | 5.68% -1.461 pp | 0.04% +0.011 pp | USD2.37 +57.0% | 7 qtrs — |
| 6 | BLACKROCK, INC. | 15.60M +526.0K (+3.5%) | 58.02M +25.2M (+76.6%) | 5.50% +0.179 pp | 0.00% +0.000 pp | USD2.76 +34.8% | 6 qtrs — |
| 7 | SUVRETTA CAPITAL MANAGEMENT, LLC | 14.50M +— (+0.0%) | 53.95M +22.3M (+70.6%) | 5.11% -0.006 pp | 1.11% +0.296 pp | USD2.26 +64.6% | 7 qtrs — |
| 8 | PARADIGM BIOCAPITAL ADVISORS LP | 14.16M +599.1K (+4.4%) | 52.67M +23.1M (+78.2%) | 4.99% +0.206 pp | 1.34% +0.504 pp | USD2.44 +52.5% | 7 qtrs — |
| 9 | LOGOS GLOBAL MANAGEMENT LP | 13.00M -2.2M (-14.2%) | 48.36M +15.3M (+46.4%) | 4.58% -0.764 pp | 2.92% -0.038 pp | USD2.35 +58.3% | 7 qtrs — |
| 10 | VANGUARD GROUP INC | 12.81M +324.0 (+0.0%) | 47.66M +19.7M (+70.6%) | 4.52% -0.005 pp | 0.00% +0.000 pp | USD4.82 -22.8% | 18 qtrs — |
| 11 | ARCH VENTURE MANAGEMENT, LLC | 11.06M +— (+0.0%) | 41.13M +17.0M (+70.6%) | 3.90% -0.005 pp | 6.31% +1.416 pp | USD15.58 -76.1% | 17 qtrs — |
| 12 | VIVO CAPITAL, LLC | 9.27M +— (+0.0%) | 34.50M +14.3M (+70.6%) | 3.27% -0.004 pp | 2.23% +0.603 pp | USD2.37 +57.0% | 7 qtrs — |
| 13 | SIREN, L.L.C. | 8.76M +— (+0.0%) | 32.58M +13.5M (+70.6%) | 3.09% -0.004 pp | 0.97% +0.225 pp | USD2.73 +36.3% | 6 qtrs — |
| 14 | STATE STREET CORP | 6.17M +2.1M (+53.2%) | 22.97M +14.2M (+161.5%) | 2.18% +0.755 pp | 0.00% +0.001 pp | USD3.60 +3.3% | 18 qtrs — |
| 15 | 5AM VENTURE MANAGEMENT, LLC | 5.41M +— (+0.0%) | 20.11M +8.3M (+70.6%) | 1.91% -0.002 pp | 6.32% +2.006 pp | USD2.44 +52.5% | 7 qtrs — |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 4.93M +77.8K (+1.6%) | 18.33M +7.8M (+73.4%) | 1.74% +0.025 pp | 0.00% +0.001 pp | USD4.86 -23.5% | 18 qtrs — |
| 17 | AFFINITY ASSET ADVISORS, LLC | 3.90M -385.8K (-9.0%) | 14.51M +5.2M (+55.3%) | 1.37% -0.138 pp | 0.83% +0.013 pp | USD2.01 +85.1% | 7 qtrs — |
| 18 | GOLDMAN SACHS GROUP INC | 3.33M +814.2K (+32.3%) | 12.39M +6.9M (+125.8%) | 1.17% +0.286 pp | 0.00% +0.001 pp | USD3.11 +19.6% | 17 qtrs — |
| 19 | AH CAPITAL MANAGEMENT, L.L.C. | 2.86M +— (+0.0%) | 10.65M +4.4M (+70.6%) | 1.01% -0.001 pp | 0.67% +0.227 pp | USD2.13 +74.6% | 9 qtrs — |
| 20 | MILLENNIUM MANAGEMENT LLC | 2.24M -676.9K (-23.2%) | 8.33M +2.0M (+31.0%) | 0.79% -0.240 pp | 0.00% +0.001 pp | USD2.42 +53.7% | 14 qtrs — |
| 21 | SOLEUS CAPITAL MANAGEMENT, L.P. | 2.16M +— (+0.0%) | 8.04M +3.3M (+70.6%) | 0.76% -0.001 pp | 0.30% +0.059 pp | USD2.44 +52.5% | 7 qtrs — |
| 22 | CAPTION MANAGEMENT, LLC | 1.99M +2.0M (+100.0%) | 7.39M +7.4M (+100.0%) | 0.70% +0.701 pp | 0.05% +0.051 pp | USD3.72 +0.0% | 1 qtrs NEW |
| 23 | WOODLINE PARTNERS LP | 1.93M +396.3K (+25.8%) | 7.18M +3.8M (+114.7%) | 0.68% +0.139 pp | 0.03% +0.012 pp | USD2.66 +39.8% | 11 qtrs — |
| 24 | DIMENSIONAL FUND ADVISORS LP | 1.78M +403.8K (+29.4%) | 6.60M +3.6M (+120.8%) | 0.63% +0.142 pp | 0.00% +0.001 pp | USD2.81 +32.4% | 13 qtrs — |
| 25 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.67M -52.0K (-3.0%) | 6.23M +2.5M (+65.5%) | 0.59% -0.019 pp | 0.00% +0.000 pp | USD4.34 -14.3% | 18 qtrs — |
| 26 | BANK OF AMERICA CORP /DE/ | 1.61M +77.6K (+5.1%) | 6.00M +2.7M (+79.3%) | 0.57% +0.027 pp | 0.00% +0.000 pp | USD2.76 +34.8% | 18 qtrs — |
| 27 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 1.49M +1.5M (+100.0%) | 5.55M +5.5M (+100.0%) | 0.53% +0.526 pp | 0.04% +0.044 pp | USD3.72 +0.0% | 1 qtrs NEW |
| 28 | NORTHERN TRUST CORP | 1.33M -112.0K (-7.8%) | 4.95M +1.8M (+57.4%) | 0.47% -0.040 pp | 0.00% +0.000 pp | USD5.57 -33.2% | 18 qtrs — |
| 29 | SILVERARC CAPITAL MANAGEMENT, LLC | 1.32M -50.5K (-3.7%) | 4.90M +1.9M (+64.3%) | 0.46% -0.018 pp | 0.68% +0.279 pp | USD2.44 +52.5% | 8 qtrs — |
| 30 | JPMORGAN CHASE & CO | 1.15M -116.0K (-9.1%) | 4.29M +1.5M (+55.1%) | 0.41% -0.041 pp | 0.00% +0.000 pp | USD2.53 +47.0% | 18 qtrs — |
| 31 | CITADEL ADVISORS LLC | 1.03M +688.5K (+201.4%) | 3.83M +3.1M (+414.4%) | 0.36% +0.243 pp | 0.00% +0.001 pp | USD3.21 +15.9% | 18 qtrs — |
| 32 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 951.7K +951.7K (+100.0%) | 3.54M +3.5M (+100.0%) | 0.34% +0.336 pp | 0.18% +0.182 pp | USD3.72 +0.0% | 1 qtrs NEW |
| 33 | JANE STREET GROUP, LLC | 912.5K +526.5K (+136.4%) | 3.39M +2.6M (+303.3%) | 0.32% +0.185 pp | 0.00% +0.000 pp | USD2.94 +26.5% | 16 qtrs — |
| 34 | TANG CAPITAL MANAGEMENT LLC | 900.0K -602.9K (-40.1%) | 3.35M +71.6K (+2.2%) | 0.32% -0.213 pp | 0.17% +0.039 pp | USD1.76 +111.4% | 9 qtrs — |
| 35 | RENAISSANCE TECHNOLOGIES LLC | 850.1K -164.9K (-16.2%) | 3.16M +949.7K (+42.9%) | 0.30% -0.059 pp | 0.00% +0.002 pp | USD2.47 +50.6% | 16 qtrs — |
| 36 | MORGAN STANLEY | 810.4K +541.7K (+201.6%) | 3.01M +2.4M (+414.7%) | 0.29% +0.191 pp | 0.00% +0.000 pp | USD3.45 +7.8% | 18 qtrs — |
| 37 | IKARIAN CAPITAL, LLC | 735.4K +735.4K (+100.0%) | 2.74M +2.7M (+100.0%) | 0.26% +0.259 pp | 0.21% +0.214 pp | USD3.72 +0.0% | 1 qtrs NEW |
| 38 | AQR CAPITAL MANAGEMENT LLC | 669.9K +5.5K (+0.8%) | 2.49M +1.0M (+72.1%) | 0.24% +0.002 pp | 0.00% +0.000 pp | USD1.43 +160.1% | 10 qtrs — |
| 39 | BANK OF NEW YORK MELLON CORP | 546.8K -27.2K (-4.7%) | 2.03M +782.8K (+62.6%) | 0.19% -0.010 pp | 0.00% +0.000 pp | USD5.89 -36.8% | 18 qtrs — |
| 40 | WELLINGTON MANAGEMENT GROUP LLP | 543.2K -57.4K (-9.6%) | 2.02M +711.4K (+54.3%) | 0.19% -0.021 pp | 0.00% +0.000 pp | USD1.97 +88.8% | 5 qtrs — |
| 41 | HRT FINANCIAL LP | 536.9K +536.9K (+100.0%) | 2.00M +2.0M (+100.0%) | 0.19% +0.189 pp | 0.01% +0.006 pp | USD3.72 +0.0% | 3 qtrs — |
| 42 | FMR LLC | 521.5K +101.9K (+24.3%) | 1.94M +1.0M (+112.1%) | 0.18% +0.036 pp | 0.00% +0.000 pp | USD2.53 +47.0% | 18 qtrs — |
| 43 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 439.6K +421.0K (+2,263.4%) | 1.64M +1.6M (+3,933.0%) | 0.16% +0.148 pp | 0.00% +0.000 pp | USD3.65 +1.9% | 2 qtrs — |
| 44 | NUVEEN, LLC | 424.7K -25.3K (-5.6%) | 1.58M +598.8K (+61.0%) | 0.15% -0.009 pp | 0.00% +0.000 pp | USD1.37 +171.5% | 4 qtrs — |
| 45 | BARCLAYS PLC | 402.8K +58.9K (+17.1%) | 1.50M +559.5K (+59.6%) | 0.14% +0.021 pp | 0.00% +0.000 pp | USD2.60 +43.1% | 16 qtrs — |
| 46 | CREATIVE PLANNING | 381.7K +31.4K (+9.0%) | 1.42M +656.2K (+85.9%) | 0.13% +0.011 pp | 0.00% +0.000 pp | USD1.80 +106.7% | 7 qtrs — |
| 47 | SIMPLEX TRADING, LLC | 346.1K +234.7K (+210.8%) | 1.29M +1.0M (+432.0%) | 0.12% +0.083 pp | 0.00% +0.001 pp | USD3.14 +18.5% | 11 qtrs — |
| 48 | INVESCO LTD. | 329.8K +47.8K (+16.9%) | 1.23M +612.0K (+99.5%) | 0.12% +0.017 pp | 0.00% +0.000 pp | USD2.64 +40.9% | 17 qtrs — |
| 49 | SQUAREPOINT OPS LLC | 258.3K +173.6K (+204.9%) | 960.8K +776.1K (+420.3%) | 0.09% +0.061 pp | 0.00% +0.001 pp | USD3.21 +15.9% | 16 qtrs — |
| 50 | DAFNA CAPITAL MANAGEMENT LLC | 254.4K -95.6K (-27.3%) | 946.5K +183.5K (+24.1%) | 0.09% -0.034 pp | 0.22% +0.031 pp | USD1.37 +171.5% | 4 qtrs — |
| 51 | TD ASSET MANAGEMENT INC | 229.8K -26.2K (-10.2%) | 855.0K +296.9K (+53.2%) | 0.08% -0.009 pp | 0.00% +0.000 pp | USD2.65 +40.4% | 6 qtrs — |
| 52 | WELLS FARGO & COMPANY/MN | 220.1K +61.5K (+38.8%) | 818.9K +473.1K (+136.8%) | 0.08% +0.022 pp | 0.00% +0.000 pp | USD2.94 +26.5% | 18 qtrs — |
| 53 | ALLIANCEBERNSTEIN L.P. | 208.8K -24.6K (-10.5%) | 776.8K +267.9K (+52.6%) | 0.07% -0.009 pp | 0.00% +0.000 pp | USD9.04 -58.8% | 18 qtrs — |
| 54 | D. E. SHAW & CO., INC. | 201.9K +201.9K (+100.0%) | 751.2K +751.2K (+100.0%) | 0.07% +0.071 pp | 0.00% +0.000 pp | USD3.72 +0.0% | 1 qtrs NEW |
| 55 | RHUMBLINE ADVISERS | 189.0K -12.5K (-6.2%) | 703.1K +263.7K (+60.0%) | 0.07% -0.005 pp | 0.00% +0.000 pp | USD5.83 -36.2% | 18 qtrs — |
| 56 | BOOTHBAY FUND MANAGEMENT, LLC | 188.5K +188.5K (+100.0%) | 701.1K +701.1K (+100.0%) | 0.07% +0.066 pp | 0.01% +0.011 pp | USD3.72 +0.0% | 1 qtrs NEW |
| 57 | UBS GROUP AG | 170.5K +24.4K (+16.7%) | 634.4K +315.7K (+99.1%) | 0.06% +0.009 pp | 0.00% +0.000 pp | USD1.98 +87.9% | 14 qtrs — |
| 58 | AMERICAN CENTURY COMPANIES INC | 165.4K +129.9K (+366.4%) | 615.1K +537.8K (+695.9%) | 0.06% +0.046 pp | 0.00% +0.000 pp | USD3.39 +9.7% | 18 qtrs — |
| 59 | HUDSON BAY CAPITAL MANAGEMENT LP | 158.0K +158.0K (+100.0%) | 587.8K +587.8K (+100.0%) | 0.06% +0.056 pp | 0.00% +0.002 pp | USD3.72 +0.0% | 1 qtrs NEW |
| 60 | RTW INVESTMENTS, LP | 146.7K +146.7K (+100.0%) | 545.5K +545.5K (+100.0%) | 0.05% +0.052 pp | 0.01% +0.006 pp | USD3.72 +0.0% | 1 qtrs NEW |
| 61 | PALUMBO WEALTH MANAGEMENT LLC | 139.4K +14.9K (+11.9%) | 518.5K +247.0K (+91.0%) | 0.05% +0.005 pp | 0.13% +0.041 pp | USD1.75 +112.6% | 8 qtrs — |
| 62 | RAFFERTY ASSET MANAGEMENT, LLC | 131.0K +131.0K (+100.0%) | 487.4K +487.4K (+100.0%) | 0.05% +0.046 pp | 0.00% +0.002 pp | USD3.72 +0.0% | 1 qtrs NEW |
| 63 | DEUTSCHE BANK AG\ | 122.0K -43.9K (-26.5%) | 453.8K +92.1K (+25.5%) | 0.04% -0.016 pp | 0.00% +0.000 pp | USD2.18 +70.6% | 18 qtrs — |
| 64 | PANAGORA ASSET MANAGEMENT INC | 118.2K +15.8K (+15.5%) | 439.8K +216.6K (+97.0%) | 0.04% +0.006 pp | 0.00% +0.001 pp | USD2.00 +86.0% | 3 qtrs — |
| 65 | PRICE T ROWE ASSOCIATES INC /MD/ | 103.5K +9.9K (+10.6%) | 386.0K +181.0K (+88.3%) | 0.04% +0.004 pp | 0.00% +0.000 pp | USD2.96 +25.7% | 14 qtrs — |
| 66 | BALYASNY ASSET MANAGEMENT L.P. | 98.1K -2.4K (-2.4%) | 364.8K +145.8K (+66.6%) | 0.03% -0.001 pp | 0.00% +0.000 pp | USD2.06 +80.6% | 3 qtrs — |
| 67 | CITIGROUP INC | 95.8K +80.5K (+528.2%) | 356.3K +323.0K (+971.9%) | 0.03% +0.028 pp | 0.00% +0.000 pp | USD3.54 +5.1% | 18 qtrs — |
| 68 | INTECH INVESTMENT MANAGEMENT LLC | 90.7K +10.7K (+13.4%) | 337.5K +163.1K (+93.6%) | 0.03% +0.004 pp | 0.00% +0.002 pp | USD2.48 +50.0% | 6 qtrs — |
| 69 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 88.2K +6.7K (+8.2%) | 326.8K +149.1K (+83.9%) | 0.03% +0.002 pp | 0.00% +0.000 pp | USD2.70 +37.8% | 7 qtrs — |
| 70 | METLIFE INVESTMENT MANAGEMENT, LLC | 80.4K -9.7K (-10.8%) | 299.0K +102.7K (+52.3%) | 0.03% -0.003 pp | 0.00% +0.001 pp | USD4.79 -22.3% | 18 qtrs — |
| 71 | CRESSET ASSET MANAGEMENT, LLC | 79.9K +— (+0.0%) | 297.3K +123.1K (+70.6%) | 0.03% +0.000 pp | 0.00% +0.001 pp | USD2.49 +49.4% | 5 qtrs — |
| 72 | VIRTUS INVESTMENT ADVISERS, INC. | 73.9K -475.0 (-0.6%) | 274.9K +112.8K (+69.6%) | 0.03% 0.000 pp | 0.07% +0.028 pp | USD1.51 +146.4% | 4 qtrs — |
| 73 | SCIENTECH RESEARCH LLC | 72.2K +72.2K (+100.0%) | 268.6K +268.6K (+100.0%) | 0.03% +0.026 pp | 0.17% +0.169 pp | USD3.72 +0.0% | 1 qtrs NEW |
| 74 | MARSHALL WACE, LLP | 62.0K -464.0K (-88.2%) | 230.5K -916.2K (-79.9%) | 0.02% -0.164 pp | 0.00% -0.001 pp | USD2.41 +54.4% | 9 qtrs — |
| 75 | CERITY PARTNERS LLC | 61.5K +121.0 (+0.2%) | 228.9K +95.0K (+71.0%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD1.39 +167.6% | 4 qtrs — |
| 76 | IEQ CAPITAL, LLC | 60.3K -2.9K (-4.5%) | 224.5K +86.7K (+62.9%) | 0.02% -0.001 pp | 0.00% +0.000 pp | USD1.35 +175.6% | 4 qtrs — |
| 77 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 59.1K +21.8K (+58.4%) | 219.8K +138.5K (+170.3%) | 0.02% +0.008 pp | 0.00% +0.002 pp | USD2.17 +71.4% | 3 qtrs — |
| 78 | NEW YORK STATE COMMON RETIREMENT FUND | 55.6K -4.9K (-8.1%) | 206.7K +74.9K (+56.8%) | 0.02% -0.002 pp | 0.00% +0.000 pp | USD4.73 -21.4% | 18 qtrs — |
| 79 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 54.8K -7.0K (-11.4%) | 203.7K +69.0K (+51.2%) | 0.02% -0.003 pp | 0.00% +0.000 pp | USD6.85 -45.7% | 18 qtrs — |
| 80 | TUDOR INVESTMENT CORP ET AL | 53.4K +53.4K (+100.0%) | 198.8K +198.8K (+100.0%) | 0.02% +0.019 pp | 0.00% +0.000 pp | USD3.72 +0.0% | 1 qtrs NEW |
| 81 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 52.7K -38.0K (-41.9%) | 196.2K -1.7K (-0.8%) | 0.02% -0.013 pp | 0.00% +0.001 pp | USD1.27 +192.9% | 5 qtrs — |
| 82 | PROFUND ADVISORS LLC | 50.6K +50.6K (+100.0%) | 188.3K +188.3K (+100.0%) | 0.02% +0.018 pp | 0.01% +0.006 pp | USD3.72 +0.0% | 1 qtrs NEW |
| 83 | SG AMERICAS SECURITIES, LLC | 48.7K +34.1K (+233.3%) | 181.0K +149.0K (+465.6%) | 0.02% +0.012 pp | 0.00% +0.000 pp | USD3.26 +14.1% | 10 qtrs — |
| 84 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 46.2K -3.5K (-7.0%) | 172.0K +63.6K (+58.7%) | 0.02% -0.001 pp | 0.01% +0.004 pp | USD2.53 +47.0% | 14 qtrs — |
| 85 | PROSHARE ADVISORS LLC | 44.2K +4.4K (+11.1%) | 164.5K +77.7K (+89.6%) | 0.02% +0.002 pp | 0.00% +0.000 pp | USD5.53 -32.7% | 17 qtrs — |
| 86 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 44.0K -15.1K (-25.6%) | 163.8K +34.8K (+27.0%) | 0.02% -0.005 pp | 0.00% +0.000 pp | USD2.39 +55.6% | 5 qtrs — |
| 87 | JAIN GLOBAL LLC | 42.3K +42.3K (+100.0%) | 157.5K +157.5K (+100.0%) | 0.01% +0.015 pp | 0.00% +0.001 pp | USD3.72 +0.0% | 4 qtrs — |
| 88 | TWO SIGMA INVESTMENTS, LP | 38.0K -309.7K (-89.1%) | 141.4K -616.7K (-81.3%) | 0.01% -0.109 pp | 0.00% -0.001 pp | USD2.67 +39.3% | 16 qtrs — |
| 89 | BAILARD, INC. | 35.2K +35.2K (+100.0%) | 131.1K +131.1K (+100.0%) | 0.01% +0.012 pp | 0.00% +0.003 pp | USD3.72 +0.0% | 1 qtrs NEW |
| 90 | VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC | 34.7K -143.0 (-0.4%) | 128.9K +53.1K (+69.9%) | 0.01% 0.000 pp | 0.00% +0.001 pp | USD1.58 +135.4% | 9 qtrs — |
| 91 | CWM, LLC | 33.6K +305.0 (+0.9%) | 125.0K +52.0K (+71.2%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD1.43 +160.1% | 10 qtrs — |
| 92 | VOYA INVESTMENT MANAGEMENT LLC | 33.2K +— (+0.0%) | 123.5K +51.1K (+70.6%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD3.85 -3.4% | 15 qtrs — |
| 93 | BNP PARIBAS ARBITRAGE, SNC | 32.5K -5.7K (-14.9%) | 120.8K +37.7K (+45.3%) | 0.01% -0.002 pp | 0.00% +0.000 pp | USD2.11 +76.3% | 5 qtrs — |
| 94 | Y-INTERCEPT (HONG KONG) LTD | 24.3K +24.3K (+100.0%) | 90.4K +90.4K (+100.0%) | 0.01% +0.009 pp | 0.00% +0.002 pp | USD3.72 +0.0% | 1 qtrs NEW |
| 95 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 22.5K +362.0 (+1.6%) | 81.7K +26.8K (+48.8%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD1.44 +158.3% | 4 qtrs — |
| 96 | AXQ CAPITAL, LP | 20.5K +20.5K (+100.0%) | 76.1K +76.1K (+100.0%) | 0.01% +0.007 pp | 0.02% +0.017 pp | USD3.72 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.50
Neutral
Ratio by volume
0.50
Neutral
Buys
1
Sells
2
Shares acquired
80.0K
Shares disposed
160.0K
Cash buys
—
Cash sales
1.00
Net activity
-80,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Garner Ebun | Officer | M-Exempt | D | Stock Option (right to buy) | 80,000 | 1.70 | 136.0K | 280,000 | D | ↗ |
| 2026-03-04 | Morris Shannon | Officer | M-Exempt | A | Common Stock | 20,000 | 1.70 | 34.0K | 20,000 | D | ↗ |
| 2026-01-29 | Varney Michael David | Director | A-Award | A | Stock option (right to buy) | 96,000 | 10.31 | 989.8K | 96,000 | D | ↗ |
| 2026-01-29 | Morris Shannon | Officer | A-Award | A | Stock option (right to buy) | 625,000 | 10.31 | 6.44M | 625,000 | D | ↗ |
| 2026-01-29 | Lim Jonathan E | Director / Officer / 10% Owner | A-Award | A | Stock option (right to buy) | 2,000,000 | 10.31 | 20.62M | 2,000,000 | D | ↗ |
| 2026-01-29 | Garner Ebun | Officer | A-Award | A | Stock option (right to buy) | 560,000 | 10.31 | 5.77M | 560,000 | D | ↗ |
| 2026-01-29 | Chacko David M. | Officer | A-Award | A | Stock option (right to buy) | 640,000 | 10.31 | 6.60M | 640,000 | D | ↗ |
| 2026-01-07 | Garner Ebun | Officer | M-Exempt | A | Common Stock | 120,000 | 1.70 | 204.0K | 145,076 | D | ↗ |
| 2026-01-01 | Start Valerie Denise Harding | Director | A-Award | A | Stock Option (right to buy) | 24,306 | 3.72 | 90.4K | 24,306 | D | ↗ |
| 2026-01-01 | Multani Pratik S | Director | A-Award | A | Stock Option (right to buy) | 19,532 | 3.72 | 72.7K | 19,532 | D | ↗ |
| 2026-01-01 | LIU JEAN I | Director | A-Award | A | Stock Option (right to buy) | 20,617 | 3.72 | 76.7K | 20,617 | D | ↗ |
| 2026-01-01 | Casdin Alexander W. | Director | A-Award | A | Stock Option (right to buy) | 23,872 | 3.72 | 88.8K | 23,872 | D | ↗ |
| 2026-01-01 | Bristol James Arthur | Director | A-Award | A | Stock Option (right to buy) | 37,762 | 3.72 | 140.5K | 37,762 | D | ↗ |
| 2025-12-15 | Garner Ebun | Officer | A-Award | A | Common Stock | 3,902 | 1.19 | 4.7K | 25,076 | D | ↗ |
| 2025-12-15 | Chacko David M. | Officer | J-Other | A | Common Stock | 17,793 | 1.19 | 21.3K | 279,980 | D | ↗ |
| 2025-06-24 | Varney Michael David | Director | A-Award | A | Stock option (right to buy) | 120,000 | 1.45 | 174.0K | 120,000 | D | ↗ |
| 2025-06-24 | Start Valerie Denise Harding | Director | A-Award | A | Stock option (right to buy) | 120,000 | 1.45 | 174.0K | 120,000 | D | ↗ |
| 2025-06-24 | Multani Pratik S | Director | A-Award | A | Stock option (right to buy) | 120,000 | 1.45 | 174.0K | 120,000 | D | ↗ |
| 2025-06-24 | LIU JEAN I | Director | A-Award | A | Stock option (right to buy) | 120,000 | 1.45 | 174.0K | 120,000 | D | ↗ |
| 2025-06-24 | Hambleton Julie | Director | A-Award | A | Stock option (right to buy) | 120,000 | 1.45 | 174.0K | 120,000 | D | ↗ |
| 2025-06-24 | Casdin Alexander W. | Director | A-Award | A | Stock option (right to buy) | 120,000 | 1.45 | 174.0K | 120,000 | D | ↗ |
| 2025-06-24 | Bristol James Arthur | Director | A-Award | A | Stock option (right to buy) | 120,000 | 1.45 | 174.0K | 120,000 | D | ↗ |
| 2025-05-23 | Multani Pratik S | Director | G-Gift | D | Common Stock | 6,200 | 0.00 | — | 166,666 | D | ↗ |
| 2025-03-04 | Morris Shannon | Officer | M-Exempt | D | Stock Option (right to buy) | 20,000 | 1.70 | 34.0K | 515,800 | D | ↗ |
| 2025-02-13 | Garner Ebun | Officer | A-Award | A | Stock option (right to buy) | 50,000 | 1.63 | 81.5K | 50,000 | D | ↗ |
| 2025-02-03 | Morris Shannon | Officer | A-Award | A | Stock option (right to buy) | 780,000 | 1.76 | 1.37M | 780,000 | D | ↗ |
| 2025-02-03 | Lim Jonathan E | Director / Officer / 10% Owner | A-Award | A | Stock option (right to buy) | 2,500,000 | 1.76 | 4.40M | 2,500,000 | D | ↗ |
| 2025-02-03 | Garner Ebun | Officer | A-Award | A | Stock option (right to buy) | 700,000 | 1.76 | 1.23M | 700,000 | D | ↗ |
| 2025-02-03 | Chacko David M. | Officer | A-Award | A | Stock option (right to buy) | 800,000 | 1.76 | 1.41M | 800,000 | D | ↗ |
| 2025-01-07 | Garner Ebun | Officer | M-Exempt | D | Stock Option (right to buy) | 120,000 | 1.70 | 204.0K | 360,000 | D | ↗ |
| 2025-01-01 | Start Valerie Denise Harding | Director | A-Award | A | Stock Option (right to buy) | 29,402 | 2.51 | 73.8K | 29,402 | D | ↗ |
| 2025-01-01 | LIU JEAN I | Director | A-Award | A | Stock Option (right to buy) | 24,939 | 2.51 | 62.6K | 24,939 | D | ↗ |
| 2025-01-01 | Casdin Alexander W. | Director | A-Award | A | Stock Option (right to buy) | 28,877 | 2.51 | 72.5K | 28,877 | D | ↗ |
| 2025-01-01 | Bristol James Arthur | Director | A-Award | A | Stock Option (right to buy) | 45,678 | 2.51 | 114.7K | 45,678 | D | ↗ |
| 2024-12-13 | Garner Ebun | Officer | J-Other | A | Common Stock | 5,731 | 1.56 | 9.0K | 21,174 | D | ↗ |
| 2024-12-13 | Chacko David M. | Officer | J-Other | A | Common Stock | 12,324 | 1.56 | 19.3K | 262,187 | D | ↗ |
| 2024-06-20 | Varney Michael David | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 2.03 | 121.8K | 60,000 | — | ↗ |
| 2024-06-20 | Start Valerie Denise Harding | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 2.03 | 121.8K | 60,000 | — | ↗ |
| 2024-06-20 | Multani Pratik S | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 2.03 | 121.8K | 60,000 | — | ↗ |
| 2024-06-20 | Morris Shannon | Officer | A-Award | A | Stock Option (right to buy) | 137,142 | 2.03 | 278.4K | 137,142 | — | ↗ |
| 2024-06-20 | Lim Jonathan E | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 632,759 | 2.03 | 1.28M | 632,759 | — | ↗ |
| 2024-06-20 | LIU JEAN I | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 2.03 | 121.8K | 60,000 | — | ↗ |
| 2024-06-20 | Hambleton Julie | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 2.03 | 121.8K | 60,000 | — | ↗ |
| 2024-06-20 | Garner Ebun | Officer | A-Award | A | Stock Option (right to buy) | 160,082 | 2.03 | 325.0K | 160,082 | — | ↗ |
| 2024-06-20 | Chacko David M. | Officer | A-Award | A | Stock Option (right to buy) | 278,812 | 2.03 | 566.0K | 278,812 | — | ↗ |
| 2024-06-20 | Casdin Alexander W. | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 2.03 | 121.8K | 60,000 | — | ↗ |
| 2024-06-20 | Bristol James Arthur | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 2.03 | 121.8K | 60,000 | — | ↗ |
| 2024-05-21 | Casdin Alexander W. | Director | P-Purchase | A | Common Stock | 80,000 | 2.27 | 181.9K | 573,974 | — | ↗ |
| 2024-02-05 | Morris Shannon | Officer | A-Award | A | Stock Option (right to buy) | 535,800 | 1.70 | 910.9K | 535,800 | — | ↗ |
| 2024-02-05 | Lim Jonathan E | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 1,500,000 | 1.70 | 2.55M | 1,500,000 | — | ↗ |
| 2024-02-05 | Garner Ebun | Officer | A-Award | A | Stock Option (right to buy) | 480,000 | 1.70 | 816.0K | 480,000 | — | ↗ |
| 2024-02-05 | Chacko David M. | Officer | A-Award | A | Stock Option (right to buy) | 600,000 | 1.70 | 1.02M | 600,000 | — | ↗ |
| 2024-01-01 | Start Valerie Denise Harding | Director | A-Award | A | Stock Option (right to buy) | 39,590 | 2.13 | 84.3K | 39,590 | — | ↗ |
| 2024-01-01 | Multani Pratik S | Director | A-Award | A | Stock Option (right to buy) | 32,867 | 2.13 | 70.0K | 32,867 | — | ↗ |
| 2024-01-01 | LIU JEAN I | Director | A-Award | A | Stock Option (right to buy) | 35,482 | 2.13 | 75.6K | 35,482 | — | ↗ |
| 2024-01-01 | Casdin Alexander W. | Director | A-Award | A | Stock Option (right to buy) | 41,084 | 2.13 | 87.5K | 41,084 | — | ↗ |
| 2024-01-01 | Bristol James Arthur | Director | A-Award | A | Stock Option (right to buy) | 62,747 | 2.13 | 133.7K | 62,747 | — | ↗ |
| 2023-12-15 | Garner Ebun | Officer | J-Other | A | Common Stock | 5,448 | 1.59 | 8.7K | 9,728 | — | ↗ |
| 2023-12-15 | Chacko David M. | Officer | J-Other | A | Common Stock | 7,478 | 1.59 | 11.9K | 246,726 | — | ↗ |
| 2023-12-06 | Start Valerie Denise Harding | Director | P-Purchase | A | Common Stock | 10,000 | 1.85 | 18.5K | 20,000 | — | ↗ |
| 2023-12-06 | Lim Jonathan E | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 278,150 | 1.72 | 478.4K | 12,899,360 | — | ↗ |
| 2023-12-05 | Lim Jonathan E | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 721,850 | 1.69 | 1.22M | 12,899,360 | — | ↗ |
| 2023-12-04 | Casdin Alexander W. | Director | P-Purchase | A | Common Stock | 30,000 | 1.66 | 49.8K | 493,974 | — | ↗ |
| 2023-10-05 | Lim Jonathan E | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 1,000,000 | 2.03 | 2.03M | 19,456,216 | — | ↗ |
| 2023-06-22 | Varney Michael David | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 2.66 | 159.6K | 60,000 | — | ↗ |
| 2023-06-22 | Start Valerie Denise Harding | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 2.66 | 159.6K | 60,000 | — | ↗ |
| 2023-06-22 | Multani Pratik S | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 2.66 | 159.6K | 60,000 | — | ↗ |
| 2023-06-22 | LIU JEAN I | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 2.66 | 159.6K | 60,000 | — | ↗ |
| 2023-06-22 | Hambleton Julie | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 2.66 | 159.6K | 60,000 | — | ↗ |
| 2023-06-22 | Chen Bihua | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 2.66 | 159.6K | 60,000 | — | ↗ |
| 2023-06-22 | Casdin Alexander W. | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 2.66 | 159.6K | 60,000 | — | ↗ |
| 2023-06-22 | Bristol James Arthur | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 2.66 | 159.6K | 60,000 | — | ↗ |
| 2023-06-08 | Lim Jonathan E | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 100,000 | 2.75 | 275.0K | 18,396,216 | — | ↗ |
| 2023-04-10 | Morris Shannon | Officer | A-Award | A | Stock Option (Right to Buy) | 375,000 | 2.74 | 1.03M | 375,000 | — | ↗ |
| 2023-04-10 | Casdin Alexander W. | Director | P-Purchase | A | Common Stock | 20,000 | 2.76 | 55.2K | 463,974 | — | ↗ |
| 2023-03-28 | Lim Jonathan E | Director / Officer / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-02-01 | Wei Lin | Officer | A-Award | A | Stock Option (right to buy) | 560,000 | 4.00 | 2.24M | 560,000 | — | ↗ |
| 2023-02-01 | Lim Jonathan E | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 1,500,000 | 4.00 | 6.00M | 1,500,000 | — | ↗ |
| 2023-02-01 | Garner Ebun | Officer | A-Award | A | Stock Option (right to buy) | 480,000 | 4.00 | 1.92M | 480,000 | — | ↗ |
| 2023-02-01 | Chacko David M. | Officer | A-Award | A | Stock Option (right to buy) | 600,000 | 4.00 | 2.40M | 600,000 | — | ↗ |
| 2023-01-10 | Lim Jonathan E | Officer | P-Purchase | A | Common Stock | 60,000 | 3.86 | 231.4K | 20,256,222 | — | ↗ |
| 2022-12-31 | Lim Jonathan E | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 11,899,360 | — | ↗ |
| 2022-12-21 | Start Valerie Denise Harding | Director | P-Purchase | A | Common Stock | 10,000 | 4.64 | 46.4K | 10,000 | — | ↗ |
| 2022-12-21 | Bristol James Arthur | Director | P-Purchase | A | Common Stock | 20,000 | 4.14 | 82.8K | 20,000 | — | ↗ |
| 2022-12-15 | Casdin Alexander W. | Director | P-Purchase | A | Common Stock | 20,000 | 4.87 | 97.5K | 443,974 | — | ↗ |
| 2022-12-14 | Lim Jonathan E | Officer | P-Purchase | A | Common Stock | 40,000 | 4.99 | 199.6K | 20,196,222 | — | ↗ |
| 2022-12-13 | Chen Bihua | Director | P-Purchase | A | Common Stock | 307,692 | 6.50 | 2.00M | 10,813,246 | — | ↗ |
| 2022-07-01 | Casdin Alexander W. | Director | J-Other | D | Common Stock | 750,000 | 0.00 | — | 0 | — | ↗ |
| 2022-06-22 | Varney Michael David | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2022-06-22 | Start Valerie Denise Harding | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-06-22 | Multani Pratik S | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-06-22 | Hambleton Julie | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 5.35 | 214.0K | 40,000 | — | ↗ |
| 2022-06-22 | Chen Bihua | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-06-22 | Casdin Alexander W. | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 5.35 | 214.0K | 40,000 | — | ↗ |
| 2022-06-22 | Bristol James Arthur | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-04-25 | LIU JEAN I | Director | A-Award | A | Stock Option (Right to Buy) | 80,000 | 0.00 | — | 80,000 | — | ↗ |
| 2022-02-01 | Wei Lin | Officer | J-Other | A | Common Stock | 1,562 | 11.60 | 18.1K | 314,062 | — | ↗ |
| 2022-02-01 | Lim Jonathan E | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 791,000 | 11.54 | 9.13M | 791,000 | — | ↗ |
| 2022-02-01 | Garner Ebun | Officer | A-Award | A | Stock Option (Right to Buy) | 171,110 | 11.54 | 1.97M | 171,110 | — | ↗ |
| 2022-02-01 | Chacko David M. | Officer | J-Other | A | Common Stock | 1,562 | 11.60 | 18.1K | 237,498 | — | ↗ |
| 2021-08-10 | Chen Bihua | Director | P-Purchase | A | Common Stock | 200,000 | 22.10 | 4.42M | 10,505,553 | — | ↗ |
| 2021-07-26 | Chen Bihua | Director | S-Sale | D | Common Stock | 200,000 | 18.77 | 3.75M | 10,305,553 | — | ↗ |
| 2021-07-20 | Start Valerie Denise Harding | Director | P-Purchase | A | Common Stock | 2,000 | 16.00 | 32.0K | 2,000 | — | ↗ |
| 2021-07-20 | Multani Pratik S | Director | P-Purchase | A | Common Stock | 6,200 | 16.00 | 99.2K | 172,866 | — | ↗ |
| 2021-07-20 | Lim Jonathan E | Director / Officer / 10% Owner | C-Conversion | A | Common Stock | 5,441,027 | 0.00 | — | 11,899,360 | — | ↗ |
| 2021-07-20 | Hambleton Julie | Director | P-Purchase | A | Common Stock | 6,000 | 16.00 | 96.0K | 6,000 | — | ↗ |
| 2021-07-20 | Garner Ebun | Officer | P-Purchase | A | Common Stock | 900 | 16.00 | 14.4K | 900 | — | ↗ |
| 2021-07-20 | Chen Bihua | Director | C-Conversion | A | Series B-2 Convertible Preferred Stock | 1,388,887 | 0.00 | — | 0 | — | ↗ |
| 2021-07-20 | Casdin Alexander W. | Director | C-Conversion | D | Series A Preferred Stock | 900,000 | 0.00 | — | 0 | — | ↗ |
| 2021-07-20 | ARCH Venture Partners X, LLC | 10% Owner | C-Conversion | D | Series B-1 Preferred Stock | 3,400,000 | 0.00 | — | 0 | — | ↗ |
| 2021-07-15 | Wei Lin | Officer | — | D | Stock Option (Right to Buy) | 833,333 | 3.36 | 2.80M | 0 | — | ↗ |
| 2021-07-15 | Varney Michael David | Director | — | D | Stock Option (Right to Buy) | 83,333 | 1.25 | 104.2K | 0 | — | ↗ |
| 2021-07-15 | Start Valerie Denise Harding | Director | — | D | Stock Option (Right to Buy) | 125,000 | 0.67 | 83.8K | 0 | — | ↗ |
| 2021-07-15 | Multani Pratik S | Director | — | D | Stock Option (Right to Buy) | 20,833 | 1.25 | 26.0K | 0 | — | ↗ |
| 2021-07-15 | Lim Jonathan E | Director / Officer / 10% Owner | — | I | Series A Preferred Stock | 5,067,694 | 0.00 | — | 0 | — | ↗ |
| 2021-07-15 | Hambleton Julie | Director | — | D | Stock Option (Right to Buy) | 166,666 | 5.81 | 968.3K | 0 | — | ↗ |
| 2021-07-15 | Garner Ebun | Officer | — | D | Stock Option (Right to Buy) | 609,166 | 5.81 | 3.54M | 0 | — | ↗ |
| 2021-07-15 | Chen Bihua | Director / 10% Owner | — | I | Series A Convertible Preferred Stock | 4,000,000 | 0.00 | — | 0 | — | ↗ |
| 2021-07-15 | Chacko David M. | Officer | — | D | Stock Option (Right to Buy) | 104,166 | 0.67 | 69.8K | 0 | — | ↗ |
| 2021-07-15 | Casdin Alexander W. | Director | — | D | Series A Preferred Stock | 150,000 | 0.00 | — | 0 | — | ↗ |
| 2021-07-15 | Bristol James Arthur | Director | — | D | Common Stock | 0 | 0.00 | — | 187,500 | — | ↗ |
| 2021-07-15 | ARCH Venture Partners X, LLC | 10% Owner | — | I | Series B-2 Preferred Stock | 944,444 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
310.80M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Jonathan E. Lim, M.D. Chairman, Chief Executive Officer, and Co-Founder | 670.4K | — | — | 3.14M | 482.7K | 10.5K | 4.30M | 72.93% | ↗ |
| 2 | 2025 | David M. Chacko, M.D. Chief Financial Officer and Chief Business Officer | 516.7K | — | — | 1.00M | 248.0K | 10.5K | 1.78M | 56.41% | ↗ |
| 3 | 2025 | Shannon R. Morris, M.D., Ph.D. Chief Medical Officer | 515.0K | — | — | 978.2K | 247.2K | 10.5K | 1.75M | 55.87% | ↗ |
| 4 | 2024 | Jonathan E. Lim, M.D. Chairman, Chief Executive Officer, and Co-Founder | 644.6K | — | — | 2.79M | 444.8K | 10.4K | 3.89M | 71.76% | ↗ |
| 5 | 2024 | David M. Chacko, M.D. Chief Financial Officer and Chief Business Officer | 492.1K | — | — | 1.16M | 226.4K | 10.4K | 1.88M | 61.33% | ↗ |
| 6 | 2024 | Shannon R. Morris, M.D., Ph.D. Chief Medical Officer | 486.5K | — | — | 866.9K | 223.8K | 10.4K | 1.59M | 54.61% | ↗ |
| 7 | 2023 | Jonathan E. Lim, M.D. Chairman, Chief Executive Officer, and Co-Founder | 622.8K | — | — | 4.42M | 355.0K | 9.9K | 5.41M | 81.73% | ↗ |
| 8 | 2023 | David M. Chacko, M.D. Chief Financial Officer and Chief Business Officer | 475.5K | — | — | 1.77M | 180.7K | 9.9K | 2.43M | 72.63% | ↗ |
| 9 | 2023 | Ebun S. Garner, J.D. General Counsel and Corporate Secretary | 433.0K | — | — | 1.41M | 164.5K | 9.9K | 2.02M | 69.95% | ↗ |
| 10 | 2022 | Jonathan E. Lim, M.D. Chairman and Chief Executive Officer | 593.1K | — | — | 6.58M | 338.1K | 9.2K | 7.52M | 87.50% | ↗ |
| 11 | 2022 | Jonathan E. Lim, M.D. Chairman, Chief Executive Officer, and Co-Founder | 593.1K | — | — | 6.58M | 338.1K | 9.2K | 7.52M | 87.50% | ↗ |
| 12 | 2022 | David M. Chacko, M.D. Chief Financial Officer and Chief Business Officer | 440.3K | — | — | 3.05M | 167.3K | 9.2K | 3.66M | 83.17% | ↗ |
| 13 | 2022 | David M. Chacko, M.D. Chief Financial Officer | 440.3K | — | — | 3.05M | 167.3K | 9.2K | 3.66M | 83.17% | ↗ |
| 14 | 2022 | Wei Lin, M.D Former Chief Medical Officer | 458.4K | — | — | 2.26M | 174.2K | 9.2K | 2.91M | 77.92% | ↗ |
| 15 | 2021 | Wei Lin, M.D. Chief Medical Officer | 426.3K | 200.0K | — | 2.70M | 221.5K | 153.5K | 3.71M | 72.98% | ↗ |
| 16 | 2021 | Wei Lin, M.D Former Chief Medical Officer | 426.3K | 200.0K | — | 2.70M | 221.5K | 153.5K | 3.71M | 72.98% | ↗ |
| 17 | 2021 | Ebun S. Garner General Counsel | 273.2K | — | — | 2.47M | 139.9K | 6.8K | 2.89M | 85.48% | ↗ |
| 18 | 2021 | Jonathan E. Lim, M.D. Chairman and Chief Executive Officer | 497.8K | — | — | — | 343.7K | 8.7K | 850.2K | 0.00% | ↗ |
| 19 | 2020 | Jonathan E. Lim, M.D. Chairman and Chief Executive Officer | 300.0K | — | — | 1.48M | 180.0K | — | 1.96M | 75.57% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jonathan E. Lim | Co-Founder, Chairman & Chief Executive Officer | 1M | — |
| David Chacko | Chief Financial Officer & Chief Business Officer | 775.2K | — |
| Shannon Morris | Chief Medical Officer | 772.7K | — |
| Ebun S. Garner | Chief Legal Officer & Corporate Secretary | 607.4K | male |
| Michael D. Varney | Chairman of Research & Development, Scientific Advisory Board Member and Director | 93.2K | — |
| Nik Chetwyn | Chief Operating Officer | — | — |
| Robert Shoemaker | Chief Scientific Officer | — | — |
| Lisa Tesvich-Bonora | Chief People Officer | — | — |
| Chandra D. Lovejoy | Chief Regulatory Affairs Officer | — | female |
| Dawei Xuan | Senior Vice President of Clinical Pharmacology | — | male |
| Brian L. Baker | Senior Vice President of Finance | — | male |
| Minli Xie | Senior Vice President of Pharmaceutical Development & Operations | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ERAS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
